PROM1 and neoplasm: Recent findings have also revealed that the glycosylated CD133 antigen is also a potential marker for the isolation of CSCs from a wide variety of tumor tissues, including glioblastomas, lung cancer, pancreatic adenocarcinomas, prostate cancer, colon cancer and hepatocellular carcinomas [8,10,12-14,22-24].